<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01856322</url>
  </required_header>
  <id_info>
    <org_study_id>130126</org_study_id>
    <secondary_id>13-C-0126</secondary_id>
    <nct_id>NCT01856322</nct_id>
  </id_info>
  <brief_title>Surgery Plus Sulindac or Surgery Alone for Advanced Colorectal Cancer</brief_title>
  <official_title>Phase 2 Prospective Randomized Double Blind Trial Comparing Metastasectomy Plus Sulindac Versus Metastasectomy Alone in Patients With Stage IV Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background:&#xD;
&#xD;
      - Some types of inflammation may increase the risk of cancers in the intestinal track.&#xD;
      Because of this possibility, anti-inflammatory drugs may be able to prevent tumor growth and&#xD;
      spread. One such drug, sulindac, may be helpful to study. Researchers want to see if people&#xD;
      who are having surgery to remove intestinal tumors from advanced colorectal cancer will&#xD;
      benefit from sulindac. It will be tested against a placebo.&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
      - To see if sulindac can improve treatment outcomes in people who are having surgery for&#xD;
      advanced colorectal cancer.&#xD;
&#xD;
      Eligibility:&#xD;
&#xD;
      - Individuals at least 18 years of age who are having surgery for advanced colorectal cancer.&#xD;
&#xD;
      Design:&#xD;
&#xD;
        -  Participants will be screened with a physical exam and medical history. Blood samples&#xD;
           will be collected. Imaging studies and heart and lung function tests may also be given.&#xD;
&#xD;
        -  Participants will be separated into two groups. One group will take sulindac. The other&#xD;
           will take a placebo.&#xD;
&#xD;
        -  Participants will take sulindac or placebo twice daily from about 2 to 3 weeks before&#xD;
           the scheduled surgery. Seven days before the surgery, they will stop taking the pills.&#xD;
&#xD;
        -  Participants will have surgery to remove their tumors. The surgery will also remove&#xD;
           affected organ tissue.&#xD;
&#xD;
        -  Participants will start to take the pills again once they have recovered from surgery.&#xD;
           They will continue taking the sulindac or placebo twice a day for 3 years, or for as&#xD;
           long as the tumors do not return.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Despite strong evidence for a causative role of inflammatory mediators in intestinal&#xD;
           cancer, the underlying mechanisms remain obscure. Established evidence indicates&#xD;
           activation of the Wnt/beta-catenin pathway is an early step in the malignant&#xD;
           transformation of colorectal adenomas with persistent activation in 90% of colorectal&#xD;
           cancers. Activation of this pathway ultimately effects transcription of the S100A4 gene.&#xD;
&#xD;
        -  S100A4 transcript serum levels have been shown to correlate with risk of recurrence in&#xD;
           colorectal cancer and patients with systemic metastases are found to have increased&#xD;
           S100A4 transcript expression.&#xD;
&#xD;
        -  S100A4 may be a novel prognostic biomarker in colorectal cancer.&#xD;
&#xD;
        -  Cyclooxygenase-2 is a key enzyme involved in the inflammatory response and is a key&#xD;
           target of molecular chemoprevention in colorectal adenoma prevention trials.&#xD;
&#xD;
        -  Recent studies demonstrate mitigation of Wnt/beta-catenin signaling by COX-2 inhibition&#xD;
           via administration of the non-steroidal anti-inflammatory drug (NSAID) sulindac using in&#xD;
           vitro and in vivo animal models.&#xD;
&#xD;
        -  We hypothesize that sulindac administration will abrogate Wnt/beta-catenin mediated&#xD;
           signaling and thus decrease S100A4 activity in patients with colorectal metastases.&#xD;
&#xD;
        -  We propose to define the benefit of sulindac administration to patients with colorectal&#xD;
           metastases following resection and validate the use of circulating S100A4 transcripts as&#xD;
           a novel biomarker for disease recurrence.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The trial was prematurely closed due to lack of accrual.&#xD;
  </why_stopped>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in Circulating S100A4 Transcript in Patients Receiving Sulindac 150 mg BD (Twice Daily) by Mouth Following Resection of Colorectal Cancer Metastases Compared to Those Who do Not.</measure>
    <time_frame>3 years</time_frame>
    <description>Difference in circulating S100A4 transcript levels will be determined by assessing the circulating S100A4 transcript level at initial presentation versus the circulating S100A4 transcript level post resection.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Colorectal Cancer</condition>
  <condition>Liver Metastasis</condition>
  <condition>Colorectal Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Sulindac</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>one tablet twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>one tablet twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal Volunteers (or control group)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Normal volunteers (or control group) enrolled with the only purpose to validate assays and the shipping method.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sulindac</intervention_name>
    <description>one tablet 150mg twice daily</description>
    <arm_group_label>Sulindac</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>One tablet twice daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Validate assays and shipping methods</intervention_name>
    <arm_group_label>Normal Volunteers (or control group)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -INCLUSION CRITERIA&#xD;
&#xD;
          1. Histologically confirmed colorectal adenocarcinoma with metastatic disease confined to&#xD;
             the liver, or limited extrahepatic intra-abdominal disease Note: limited sites of&#xD;
             disease include:&#xD;
&#xD;
               -  porta hepatis lymph node metastases&#xD;
&#xD;
               -  pelvic lymph node metastases (internal iliac, external iliac or obturator)&#xD;
&#xD;
          2. Hepatic and intra-abdominal metastases must be measurable by computed tomography (CT),&#xD;
             magnetic resonance imaging (MRI) and/or positron emission tomography (PET) scan&#xD;
&#xD;
          3. Liver disease must be amenable to gross total resection (R0/R1) with adequate&#xD;
             functional liver remnant which requires preservation of at least 2 contiguous hepatic&#xD;
             segments with adequate inflow, outflow, and biliary drainage with a functional liver&#xD;
             remnant (FLR) volume of more than 20% (for healthy liver)&#xD;
&#xD;
          4. Greater than or equal to 18 years of age.&#xD;
&#xD;
          5. Must be able to understand and sign the Informed Consent Documentation.&#xD;
&#xD;
          6. Clinical performance status of Eastern Cooperative Oncology Group (ECOG) less than or&#xD;
             equal to 2.&#xD;
&#xD;
          7. Life expectancy of greater than six months.&#xD;
&#xD;
          8. Patients of both genders must be willing to practice birth control during and for one&#xD;
             week after taking sulindac/placebo.&#xD;
&#xD;
          9. Hematology:&#xD;
&#xD;
               -  Absolute neutrophil count greater than 1500/mm^3 without the support of&#xD;
                  Filgrastim.&#xD;
&#xD;
               -  Platelet count greater than 75,000/mm^3.&#xD;
&#xD;
               -  Hemoglobin greater than 8.0 g/dl.&#xD;
&#xD;
         10. Chemistry:&#xD;
&#xD;
               -  Serum creatinine less than or equal to 1.5 mg/dl unless the measured creatinine&#xD;
                  clearance is greater than 60mL/min/1.73m^2.&#xD;
&#xD;
               -  Total bilirubin less than or equal to 2 mg/dl, except for patients with diagnosis&#xD;
                  of Gilberts disease or hepatic pedicle obstruction then total bilirubin must be&#xD;
                  less than or equal to 5 mg/dl.&#xD;
&#xD;
         11. International normalized ratio (INR) less than or equal to 1.8.&#xD;
&#xD;
        INCLUSION CRITERIA for NORMAL VOLUNTEERS&#xD;
&#xD;
          -  Age greater than 18&#xD;
&#xD;
          -  Able to read and understand the informed consent&#xD;
&#xD;
          -  No self-reported co morbidities of history of cancer&#xD;
&#xD;
        EXCLUSION CRITERIA&#xD;
&#xD;
          1. Women of child-bearing potential who are pregnant or breast feeding because of the&#xD;
             potentially dangerous effects of the chemotherapy on the fetus or infant.&#xD;
&#xD;
          2. Active systemic infections, coagulation disorders or other major medical illnesses&#xD;
             precluding major surgery.&#xD;
&#xD;
          3. Patients receiving warfarin anticoagulation, who cannot be transferred to other&#xD;
             agents, such as low molecular weight heparins, anti-factor Xa (anti-Xa) agents, etc.&#xD;
&#xD;
          4. Active bleeding disorders&#xD;
&#xD;
          5. Patients with uncontrolled hypertension (would suggest: systolic blood pressure (SBP)&gt;&#xD;
             155, diastolic blood pressure (DBP)&gt; 90), unstable coronary disease (unstable angina,&#xD;
             evidence of congestive heart failure (CHF), or myocardial infarction (MI) within 6-12&#xD;
             months of study)&#xD;
&#xD;
          6. Childs B or C cirrhosis or with evidence of severe portal hypertension by history,&#xD;
             endoscopy, or radiologic studies or with evidence of moderate to severe ascites.&#xD;
&#xD;
          7. Prior history of gastrointestinal (GI) bleeding unrelated to a cancer diagnosis&#xD;
&#xD;
             Note: Patients who have a normal upper and lower endoscopy may be enrolled at the&#xD;
             discretion of the principal investigator (PI).&#xD;
&#xD;
          8. Renal insufficiency Discretion of principle investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marybeth S Hughes, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Siegel R, Naishadham D, Jemal A. Cancer statistics for Hispanics/Latinos, 2012. CA Cancer J Clin. 2012 Sep-Oct;62(5):283-98. doi: 10.3322/caac.21153.</citation>
    <PMID>22987332</PMID>
  </reference>
  <reference>
    <citation>Obrand DI, Gordon PH. Incidence and patterns of recurrence following curative resection for colorectal carcinoma. Dis Colon Rectum. 1997 Jan;40(1):15-24.</citation>
    <PMID>9102255</PMID>
  </reference>
  <reference>
    <citation>de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000 Aug;18(16):2938-47.</citation>
    <PMID>10944126</PMID>
  </reference>
  <verification_date>October 2015</verification_date>
  <study_first_submitted>May 14, 2013</study_first_submitted>
  <study_first_submitted_qc>May 14, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 17, 2013</study_first_posted>
  <results_first_submitted>March 25, 2015</results_first_submitted>
  <results_first_submitted_qc>April 21, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 7, 2015</results_first_posted>
  <last_update_submitted>October 22, 2015</last_update_submitted>
  <last_update_submitted_qc>October 22, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Institutes of Health Clinical Center (CC)</investigator_affiliation>
    <investigator_full_name>Marybeth Hughes, M.D.</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Colorectal Cancer</keyword>
  <keyword>Liver Metastasis</keyword>
  <keyword>Sulindac</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sulindac</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>The normal volunteer (or control group) was not randomized to receive medication and was not considered evaluable. The control group purpose is to validate the assays and the shipping methods.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Sulindac</title>
          <description>one tablet twice daily&#xD;
Sulindac: one tablet twice daily</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>one tablet twice daily&#xD;
Placebo: One tablet twice daily</description>
        </group>
        <group group_id="P3">
          <title>Normal Volunteers (or Control Group)</title>
          <description>Normal volunteers (or control group) enrolled with the only purpose to validate assays and the shipping method.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>off study due to lack of accrual</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sulindac</title>
          <description>one tablet twice daily&#xD;
Sulindac: one tablet twice daily</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>one tablet twice daily&#xD;
Placebo: One tablet twice daily</description>
        </group>
        <group group_id="B3">
          <title>Normal Volunteers (or Control Group)</title>
          <description>Normal volunteers (or control group) enrolled with the only purpose to validate assays and the shipping method.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="0"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="3"/>
            <count group_id="B4" value="3"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="72" spread="0"/>
                    <measurement group_id="B4" value="72" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Difference in Circulating S100A4 Transcript in Patients Receiving Sulindac 150 mg BD (Twice Daily) by Mouth Following Resection of Colorectal Cancer Metastases Compared to Those Who do Not.</title>
        <description>Difference in circulating S100A4 transcript levels will be determined by assessing the circulating S100A4 transcript level at initial presentation versus the circulating S100A4 transcript level post resection.</description>
        <time_frame>3 years</time_frame>
        <population>The trial was prematurely closed due to lack of accrual, thus the outcome measure was not met.</population>
        <group_list>
          <group group_id="O1">
            <title>Sulindac</title>
            <description>one tablet twice daily&#xD;
Sulindac: one tablet twice daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>one tablet twice daily&#xD;
Placebo: One tablet twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Difference in Circulating S100A4 Transcript in Patients Receiving Sulindac 150 mg BD (Twice Daily) by Mouth Following Resection of Colorectal Cancer Metastases Compared to Those Who do Not.</title>
          <description>Difference in circulating S100A4 transcript levels will be determined by assessing the circulating S100A4 transcript level at initial presentation versus the circulating S100A4 transcript level post resection.</description>
          <population>The trial was prematurely closed due to lack of accrual, thus the outcome measure was not met.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Sulindac</title>
          <description>one tablet twice daily&#xD;
Sulindac: one tablet twice daily</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>one tablet twice daily&#xD;
Placebo: One tablet twice daily</description>
        </group>
        <group group_id="E3">
          <title>Normal Volunteers (or Control Group)</title>
          <description>Normal volunteers (or control group) enrolled with the only purpose to validate assays and the shipping method.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Marybeth Hughes</name_or_title>
      <organization>National Cancer Institute</organization>
      <phone>301-594-9341</phone>
      <email>hughesm@mail.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

